NasdaqGM - Nasdaq Real Time Price USD

MannKind Corporation (MNKD)

Compare
6.85 +0.55 (+8.73%)
At close: December 20 at 4:00:02 PM EST
6.85 -0.00 (-0.01%)
After hours: December 20 at 7:57:44 PM EST
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
267,200.00
198,962.00
99,770.00
75,442.00
65,144.00
Cost of Revenue
75,065.00
62,771.00
57,497.00
38,857.00
24,641.00
Gross Profit
192,135.00
136,191.00
42,273.00
36,585.00
40,503.00
Operating Expense
134,883.00
125,597.00
111,194.00
90,068.00
65,288.00
Operating Income
57,252.00
10,594.00
-68,921.00
-53,483.00
-24,785.00
Net Non Operating Interest Income Expense
-24,340.00
-19,007.00
-22,256.00
-16,465.00
-9,304.00
Other Income Expense
-7,877.00
-1,964.00
3,777.00
-10,978.00
-23,369.00
Pretax Income
25,035.00
-10,377.00
-87,400.00
-80,926.00
-57,458.00
Tax Provision
3,468.00
1,561.00
--
--
-218.00
Net Income Common Stockholders
21,567.00
-11,938.00
-87,400.00
-80,926.00
-57,240.00
Diluted NI Available to Com Stockholders
21,567.00
-11,938.00
-87,400.00
-80,926.00
-57,240.00
Basic EPS
0.08
-0.04
-0.34
-0.32
-0.26
Diluted EPS
0.08
-0.04
-0.34
-0.32
-0.26
Basic Average Shares
272,027.75
267,014.00
257,092.00
249,244.00
222,585.00
Diluted Average Shares
278,474.75
267,014.00
257,092.00
249,244.00
222,585.00
Total Operating Income as Reported
53,950.00
8,678.00
-64,110.00
-47,022.00
-47,913.00
Total Expenses
209,948.00
188,368.00
168,691.00
128,925.00
89,929.00
Net Income from Continuing & Discontinued Operation
21,567.00
-11,938.00
-87,400.00
-80,926.00
-57,240.00
Normalized Income
28,239.12
-10,290.06
-91,279.00
-70,187.00
-33,941.57
Interest Income
11,515.00
6,154.00
2,513.00
112.00
167.00
Interest Expense
35,855.00
25,161.00
24,769.00
16,577.00
9,471.00
Net Interest Income
-24,340.00
-19,007.00
-22,256.00
-16,465.00
-9,304.00
EBIT
60,890.00
14,784.00
-62,631.00
-64,349.00
-47,987.00
EBITDA
68,789.00
20,620.00
-56,319.00
-61,105.00
-44,661.00
Reconciled Cost of Revenue
75,065.00
62,771.00
57,497.00
38,857.00
24,641.00
Reconciled Depreciation
7,899.00
5,836.00
6,312.00
3,244.00
3,326.00
Net Income from Continuing Operation Net Minority Interest
21,567.00
-11,938.00
-87,400.00
-80,926.00
-57,240.00
Total Unusual Items Excluding Goodwill
-7,745.00
-2,086.00
3,879.00
-10,739.00
-23,392.00
Total Unusual Items
-7,745.00
-2,086.00
3,879.00
-10,739.00
-23,392.00
Normalized EBITDA
76,534.00
22,706.00
-60,198.00
-50,366.00
-21,269.00
Tax Rate for Calcs
0.00
0.00
--
--
0.00
Tax Effect of Unusual Items
-1,072.88
-438.06
--
--
-93.57
12/31/2020 - 7/28/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

UTHR United Therapeutics Corporation
359.58
-0.16%
 
GERN Geron Corporation
3.4900
-4.64%
 
TGTX TG Therapeutics, Inc.
32.20
+4.04%
 
HURA TuHURA Biosciences, Inc.
4.4800
+12.00%
 
LQDA Liquidia Corporation
11.10
+4.82%
 
RXRX Recursion Pharmaceuticals, Inc.
6.03
-0.99%
 
BLUE bluebird bio, Inc.
8.50
-7.91%
 
SGMO Sangamo Therapeutics, Inc.
2.4700
+6.93%
 
CRVS Corvus Pharmaceuticals, Inc.
4.9900
-1.96%
 
MESO Mesoblast Limited
14.63
-12.71%